Aβ Oligomers Induce Neuronal Cell Cycle Events in Alzheimer's Disease
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Neurons subject to degeneration in Alzheimer's disease (AD) exhibit evidence of re-entry into a mitotic cell cycle even before the development of substantial AD brain pathology. In efforts to identify the initiating factors underlying these cell cycle events (CCEs), we have characterized the appearance of the neuronal CCEs in the genomic-based R1.40 transgenic mouse model of AD. Notably, R1.40 mice exhibit neuronal CCEs in a reproducible temporal and spatial pattern that recapitulates the neuronal vulnerability seen in human AD. Neuronal CCEs first appear at 6 months in the frontal cortex layers II/III. This is 6–8 months before detectable amyloid β (Aβ) deposition, suggesting that specific amyloid precursor protein (APP) processing products are responsible for the induction of neuronal CCEs. Furthermore, a reduction in the levels of Aβ (achieved by shifting the genetic background from C57BL/6 to the DBA/2 mouse strain) dramatically delays the appearance of neuronal CCEs. More significantly, elimination of β-secretase activity blocks the appearance of CCEs, providing direct genetic evidence that the amyloidogenic processing of APP is required for the induction of CCEs. Finally, in vitro preparations of oligomeric, but not monomeric, Aβ induce DNA synthesis in dissociated cortical neurons, and this response is blocked by antioligomer specific antibodies. Together, our data suggest that low molecular weight aggregates of Aβ induce neuronal cell cycle re-entry in mouse models of Alzheimer's disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: A specific amyloid-β protein assembly in the brain impairs memory
Lesné, S., Koh, M. T., Kotilinek, L., Kayed, R., Glabe, C. G., Yang, A., Gallagher, M., & Ashe, K. H. (2006) · Nature · doi:10.1038/nature04533 · Cited by 2,769 · cited 2×
“…neurotoxicity of oligomers that are capable of inhibiting LTP in vivo (Walsh et al., 2002) and in hippocampal slices (Wang et al., 2002) decrease spine density (Lacor et al., 2007) and impair memory in animal models of AD independently of A deposition and neuronal cell loss (Lesné et al., 2006).”
BackgroundMethodRetractedWalsh, D. M., Klyubin, I., Fadeeva, J. V., Cullen, W. K., Anwyl, R., Wolfe, M. S., Rowan, M. J., & Selkoe, D. J. (2002) · Nature · doi:10.1038/416535a · Cited by 4,291
Triple-Transgenic Model of Alzheimer’s Disease with Plaques and Tangles
Oddo, S., Caccamo, A., Shepherd, J. D., Murphy, M. P., Golde, T. E., Kayed, R., Metherate, R., Mattson, M. P., Akbari, Y., & LaFerla, F. M. (2003) · Neuron · doi:10.1016/s0896-6273(03)00434-3 · Cited by 4,126
Diffusible, nonfibrillar ligands derived from Aβ 1–42 are potent central nervous system neurotoxins
Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506 · cited 2×
“A oligomers can also inhibit long-term potentiation (LTP), in nanomolar concentrations (Walsh et al., 2002), and they exhibit potent toxic effects capable of inducing neuronal cell death in hippocampal slices (Lambert et al., 1998).”
BackgroundFrequency of Stages of Alzheimer-Related Lesions in Different Age Categories
Braak, H., & Braak, E. (1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00056-0 · Cited by 1,656
Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology
Sturchler-Pierrat, C., Abramowski, D., Duke, M., Wiederhold, K.-H., Mistl, C., Rothacher, S., Ledermann, B., Bürki, K., Frey, P., Paganetti, P. A., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.24.13287 · Cited by 1,507
Lacor, P. N., Buniel, M. C., Furlow, P. W., Sanz Clemente, A., Velasco, P. T., Wood, M., Viola, K. L., & Klein, W. L. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.3501-06.2007 · Cited by 1,188 · cited 2×
“…neurotoxicity of oligomers that are capable of inhibiting LTP in vivo (Walsh et al., 2002) and in hippocampal slices (Wang et al., 2002) decrease spine density (Lacor et al., 2007) and impair memory in animal models of AD independently of A deposition and neuronal cell loss (Lesné et al., 2006).”
BackgroundGong, Y., Chang, L., Viola, K. L., Lacor, P. N., Lambert, M. P., Finch, C. E., Krafft, G. A., & Klein, W. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1834302100 · Cited by 1,061 · cited 2×
“Oligomeric assemblies of Aβ have been isolated from postmortem AD brains (Gong et al., 2003) as well as young, predepositing transgenic mouse models of AD (Lesné et al.”
BackgroundMethodIn vitro characterization of conditions for amyloid-β peptide oligomerization and fibrillogenesis
Stine, W. B., Dahlgren, K. N., Krafft, G. A., & LaDu, M. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210207200 · Cited by 1,015 · cited 3×
“Human A 1– 42 peptides were treated by established protocols to generate both monomeric and oligomeric A (Stine et al., 2003).”
MethodLuo, Y., Bolon, B., Kahn, S., Bennett, B. D., Babu-Khan, S., Denis, P., Fan, W., Kha, H., Zhang, J., Gong, Y., et al. (2001) · Nature Neuroscience · doi:10.1038/85059 · Cited by 1,001
De Felice, F. G., Velasco, P. T., Lambert, M. P., Viola, K., Fernandez, S. J., Ferreira, S. T., & Klein, W. L. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m607483200 · Cited by 882 · cited 1×
“…whether they exert their mitogenic effects through any of the pathways thus far identified underlying A oligomer-based neurotoxicity, such as interactions with NMDA receptors (De Felice et al., 2007), insulin signaling (Zhao et al., 2008), as well as cal- cium dysregulation (Nimmrich et al., 2008).”
BackgroundRoberds, S. L. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.12.1317 · Cited by 705 · cited 1×
“40 transgenic mice maintained on a Bace1 / background fail to exhibit evidence of CTF or production (Cai et al., 2001; Luo et al., 2001; Roberds et al., 2001), with corresponding increases in CTF and full-length APP (Fig.”
BackgroundAmyloid beta oligomers induce impairment of neuronal insulin receptors
Zhao, W., De Felice, F. G., Fernandez, S., Chen, H., Lambert, M. P., Quon, M. J., Krafft, G. A., & Klein, W. L. (2008) · The FASEB Journal · doi:10.1096/fj.06-7703com · Cited by 587 · cited 2×
“…whether they exert their mitogenic effects through any of the pathways thus far identified underlying A oligomer-based neurotoxicity, such as interactions with NMDA receptors (De Felice et al., 2007), insulin signaling (Zhao et al., 2008), as well as cal- cium dysregulation (Nimmrich et al., 2008).”
BackgroundEctopic Cell Cycle Proteins Predict the Sites of Neuronal Cell Death in Alzheimer’s Disease Brain
Busser, J., Geldmacher, D. S., & Herrup, K. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-08-02801.1998 · Cited by 543 · cited 2×
“In human AD, neuronal CCEs are observed in neurons subject to neurodegeneration in patients early in the disease process as indicated by their presence in patients with mild cognitive impairment, coupled with their virtual absence in nondemented individuals and in brain regions where there is no neuronal cell loss (Bu…”
BackgroundSelf-citationWang, H.-W., Pasternak, J. F., Kuo, H., Ristic, H., Lambert, M. P., Chromy, B., Viola, K. L., Klein, W. L., Stine, W. B., Krafft, G. A., et al. (2002) · Brain Research · doi:10.1016/s0006-8993(01)03058-x · Cited by 527 · cited 2×
“, 2002) and in hippocampal slices (Wang et al., 2002) decrease spine density (Lacor et al.”
BackgroundNeuronal cell death is preceded by cell cycle events at all stages of Alzheimer’s disease
Yang, Y., Mufson, E. J., & Herrup, K. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-07-02557.2003 · Cited by 483 · cited 3×
“…immunohistochemical analysis of brain tissue from individuals with mild cognitive impairment, believed by many to be of the clinical predecessor of AD (Petersen, 2000), reveals the presence of cell cycle events (CCEs) in brain regions that undergo substantial degeneration in AD (Yang et al., 2003).”
BackgroundSelf-citationAlzheimer's disease-type neuronal tau hyperphosphorylation induced by Aβ oligomers
De Felice, F. G., Wu, D., Lambert, M. P., Fernandez, S. J., Velasco, P. T., Lacor, P. N., Bigio, E. H., Jerecic, J., Acton, P. J., Shughrue, P. J., et al. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.02.029 · Cited by 432
Temporal Profile of Amyloid-β (Aβ) Oligomerization in an in Vivo Model of Alzheimer Disease
Oddo, S., Caccamo, A., Tran, L., Lambert, M. P., Glabe, C. G., Klein, W. L., & LaFerla, F. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m507892200 · Cited by 379 · cited 2×
“, 2003) as well as young, predepositing transgenic mouse models of AD (Lesné et al., 2006; Oddo et al., 2006; Cheng et al., 2007).”
BackgroundMethodMonoclonal antibodies that target pathological assemblies of Aβ
Lambert, M. P., Velasco, P. T., Chang, L., Viola, K. L., Fernandez, S., Lacor, P. N., Khuon, D., Gong, Y., Bigio, E. H., Shaw, P., et al. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04157.x · Cited by 314 · cited 7×
“P Lambert (Northwestern University, Evanston, IL) for providing NU1 and NU2 antibodies.”
MethodInfluentialIntroduction and expression of the 400 kilobase precursor amyloid protein gene in transgenic mice
Lamb, B. T., Sisodia, S. S., Lawler, A. M., Slunt, H. H., Kitt, C. A., Kearns, W. G., Pearson, P. L., Price, D. L., & Gearhart, J. D. (1993) · Nature Genetics · doi:10.1038/ng0993-22 · Cited by 311
Self-citationExpression of the cyclin-dependent kinase inhibitor p16 in Alzheimerʼs disease
Lars Rödel, T. A., Gärtner, U., & Holzer, M. (1996) · NeuroReport · doi:10.1097/00001756-199611250-00050 · Cited by 250
Lamb, B. (1997) · Human Molecular Genetics · doi:10.1093/hmg/6.9.1535 · Cited by 128 · cited 1×
“40 transgenic mouse strain and subsequent backcrossing to inbred strains has been described previously (Lamb et al., 1993, 1997; Lehman et al., 2003b).”
MethodSelf-citationAlterations in β-amyloid production and deposition in brain regions of two transgenic models
Lehman, E. J. H., Kulnane, L. S., & Lamb, B. T. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00153-7 · Cited by 55 · cited 3×
“40 mouse models and that the highest steady state levels of A are in the cerebellum, hippocampus, and olfactory bulb (Lehman et al., 2003a).”
BackgroundMethodSelf-citation
Cited by
The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade
Cline, E. N., Bicca, M. A., Viola, K. L., & Klein, W. L. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-179941 · Cited by 870
The case for rejecting the amyloid cascade hypothesis
Herrup, K. (2015) · Nature Neuroscience · doi:10.1038/nn.4017 · Cited by 768
Self-citationThe Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer’s disease
Ferreira, S. T., & Klein, W. L. (2011) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2011.08.003 · Cited by 442
Reimagining Alzheimer's Disease—An Age-Based Hypothesis
Herrup, K. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.4521-10.2010 · Cited by 396
Self-citationSynaptopathies: synaptic dysfunction in neurological disorders – A review from students to students
Lepeta, K., Lourenco, M. V., Schweitzer, B. C., Martino Adami, P. V., Banerjee, P., Catuara‐Solarz, S., de La Fuente Revenga, M., Guillem, A. M., Haidar, M., Ijomone, O. M., et al. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13713 · Cited by 386
Metadata
- Authors
- Varvel, N. H., Bhaskar, K., Patil, A. R., Pimplikar, S. W., Herrup, K., & Lamb, B. T.
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2008-10-22
- Volume
- 28
- Issue
- 43
- Pages
- 10786-10793
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- OpenAlex
- W2088677347
- Cited by
- 139
- References
- 23
- FWCI
- 7.24
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.